<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522168</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00084468</org_study_id>
    <nct_id>NCT03522168</nct_id>
  </id_info>
  <brief_title>Long-term Antipsychotic Pediatric Safety Trial</brief_title>
  <acronym>LAPS</acronym>
  <official_title>Pediatric Trials Network Long-term Antipsychotic Pediatric Safety Trial (LAPS) NICHD-2016-LAP01 Phase 4 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the long-term pathologic weight changes associated with multi-year
      risperidone or aripiprazole therapy in 3 - &lt;18-year-old children, who have varying durations
      of prior antipsychotic drug exposure from the start of study Month 0 (M0). This is critical
      because children appear to have greater vulnerability to antipsychotic-associated weight gain
      than adults, and obesity has significant effects on morbidity and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-site, Phase 4, longitudinal observational study designed to systematically
      collect robust longitudinal post-marketing safety and quality of life data about multi-year
      pediatric treatment with risperidone or aripiprazole. Screening may occur for up to 37 days
      prior to enrollment. Assessments will occur at in-person visits planned at months 0, 6, 12,
      18 and 24, and at unscheduled, in-person visits that study staff request when the participant
      switches or stops antipsychotic monotherapy with risperidone or aripiprazole, adds or stops
      treatment with a weight modifying agent, becomes pregnant, chooses to withdraw from the study
      prematurely or, has an ongoing Serious Adverse Event (SAE) that requires further assessment.
      Monthly remote interim contacts occurring between in-person visits will monitor for changes
      (other than dose related) in antipsychotic therapy or weight modifying treatments, potential
      SAEs, and potential pregnancy. The participant, his/her parent/guardian, and the
      participant's personal psychotropic- prescribing medical provider (PPPMP) will make any and
      all decisions related to antipsychotic medications; any other medications; and the
      participant's current mental state, developmental/psychiatric condition, and level of risk
      for potential harm to self or others independent of the study procedures and assessments.
      Study staff (SS) will share all lab results and changes in the participant's AEs or clinical
      presentation, which the study medical clinician (SMC) considers medically concerning based on
      the participant's assessment during in-person visits, with the participant's PPPMP. If an
      emergency safety concern is evident during an in-person visit, the SMC will immediately
      assess the participant, following medical standard-of- care procedures, to determine whether
      the participant is safe to leave the clinic or requires additional emergency care. If new or
      worsening symptoms are reported by the participant or parent/guardian during remote interim
      contacts, the participant and/or parent/guardian will be instructed to contact the PPPMP
      directly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BMI z-score</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Longitudinally, evaluate the long term pathologic weight changes associated with multi- year risperidone or aripiprazole therapy over a period of 24 months in children ages 3 - &lt;18 years with varying durations of prior antipsychotic drug exposure at the M0 visit. The primary analysis will focus on changes in the modified Body Mass Index (BMI) z- score in children 6 - &lt;18 years old from M0 visit over 24 months of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of weight change</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Change in BMI category and Modified BMI z-score increase of â‰¥1.0 unit from M0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic measures associated with risk of diabetes and cardiovascular disease</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Clinical laboratory evaluations for high-sensitivity C-reactive protein (hs-CRP); hemoglobin A1c (Hgb A1c); Presence of acanthosis nigricans or, in females only, hirsuitism on physical exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolactin related outcomes</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Clinical laboratory evaluation of serum prolactin; Incidence of gynecomastia in males on physical exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uniformly Elicited Events of Special Interest</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>A standardized semi-structured interview will be used by the SMC to assess events of special interest in all participants at every in-person visit [56]. The form queries for potential hospitalizations, emergency department visits, and urgent care visits and for pregnancy. The form also evaluates frequent or especially concerning adverse effects seen with antipsychotics including behavioral events. Targeted symptoms are: Sedation, Increased sleep, Problems with attention, thinking or learning Insomnia, Arrhythmias, Light-headedness (Orthostasis vs Vertigo), Seizures, Increased appetite, Decreased appetite, Tics, Tremors, Parkinsonian symptoms, Akathisia, Drooling, Dyskinesia, Polydipsia, Polyuria, Enuresis, Galactorrhea, Amenorrhea, Sexual dysfunction/anorgasmia, Diabetes, Fractures Menorrhagia, Lack of satiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Serious adverse events Adverse events (AEs) of mild (grade 1) severity and related to risperidone or aripiprazole All adverse events of moderate (grade 2) severity or greater regardless of relatedness to risperidone or aripiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidality</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Assessed using DASS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromotor effects</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Abnormal Involuntary Movement Scale (AIMS) Simpson Angus Extrapyramidal Symptoms Scale (SAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs (Adverse Events)</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Elicited AEs, including AEs of mild (grade 1) and related to risperidone or aripiprazole, and all AEs of moderate (grade 2) or greater and clinically significant changes in suicidality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefits - Pediatric Quality of Life Inventory</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Relationship of risperidone or aripiprazole therapy to adaptive functioning and quality of life as assessed by the Pediatric Quality of Life Inventory (PedsQL, 23 item), and changes in the intensity or frequency of pre-existing behavioral problems indicated at M0 (baseline). The 23-item PedsQL Generic Core Scales were designed to measure the core dimensions of health as delineated by the World Health Organization in individuals aged 2 years and older. The main scales include physical functioning, emotional functioning, social functioning, and school functioning. Summary scores can also be utilized to measure change over time on a five point scale for 0 = &quot;Never a Problem&quot; to 5 = &quot;Almost Always a Problem&quot;. The guardian will be asked to complete the parent version for reporting on their child's quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit - School and Work Questionnaire (SWQ)</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Relationship of risperidone or aripiprazole therapy with age-appropriate skip patterns, school promotions and graduations, changes in school supports, type of living situations, romantic relationships, arrests, and types and extent of employment during the interval since the prior assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefits- Caregiver Strain Questionnaire (CSQ)</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Relationship of risperidone or aripiprazole therapy to adaptive functioning and quality of life as assessed ) by the Caregiver Strain Questionnaire (CSQ) and changes in the intensity or frequency of pre-existing behavioral problems indicated at M0 (baseline). This is a 21-item questionnaire with a categorical scale ranging from 1 (not at all a problem) to 5 (very much a problem) that assesses the caregiver's quality of life. It asks specifically about the caregiver's quality of life by assessing the impact of caring for a child with emotional and behavioral problems. The questions include information about disruption of family life and relationships; demands on time; negative, mental, and physical health effects for any family member; financial strain; feelings of sacrifice; disruption of social/community life; worry/guilt; fatigue/strain; and embarrassment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefits - Delighted-Terrible Faces Scale (DTFS)</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Relationship of risperidone or aripiprazole therapy to adaptive functioning and quality of life as assessed by the Delighted-Terrible Faces Scale (DTFS) and changes in the intensity or frequency of pre-existing behavioral problems indicated at M0 (baseline). The DTFS is a uni-dimensional, single item scale that will be used to assess the participant's perceived life quality. Faces expressing various feelings are depicted, and the participant is asked which face comes closest to expressing how he/she feels about his/her life over the past month. The participant can then select from the range of seven categorical faces depicting from one-delighted to seven-terrible expressions. This scale is included because it can be easily completed by participants with limited verbal and cognitive abilities as well as by very young children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK CL/F</measure>
    <time_frame>24 months</time_frame>
    <description>CL/F, apparent total clearance of the drug from plasma after oral administration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Vss/F</measure>
    <time_frame>24 months</time_frame>
    <description>Vss/F, apparent volume of distribution at steady state after non-intravenous administration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK AUCss</measure>
    <time_frame>24 months</time_frame>
    <description>AUCss, area under the curve at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cmax</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax, maximum concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Tmax</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax, time of maximum concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK T1/2</measure>
    <time_frame>24 months</time_frame>
    <description>T1/2, half-life at steady state</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Weight, Body</condition>
  <arm_group>
    <arm_group_label>Risperidone group</arm_group_label>
    <description>Rispridone, n=350, including 30 children 3 - &lt;6 years old and 320 children 6 - &lt;18 years old. ~50% - ~80% of the entire group will have &lt;90 days of prior treatment with any antipsychotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole group</arm_group_label>
    <description>Aripiprazole group, n=350, including 30 children 3 - &lt;6 years old and 320 children 6 - &lt;18 years old. ~50% - ~80% of the entire group will have â‰¤90 days of prior treatment with any antipsychotic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder</description>
    <arm_group_label>Risperidone group</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder</description>
    <arm_group_label>Aripiprazole group</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Obtain whole blood samples for future genetic analyses that may be used to determine if there
      are any genetic factors that might be used to personalize risk assessments.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of two groups of children 3 - &lt;18 yrs old at the M0
        visit:

          -  Risperidone group, n=350, including 30 children 3 - &lt;6 yrs old and 320 children 6 -
             &lt;18 yrs old, ~ 50% - 80% will have &lt;90 days of prior treatment with any antipsychotic.

          -  Aripiprazole group, n=350, including 30 children 3 - &lt;6 yrs old and 320 children 6 -
             &lt;18 yrs old., ~ 50% - 80% will have â‰¤90 days of prior treatment with any
             antipsychotic.

        We will target participants within each treatment group to be distributed across the age
        range to permit analyses of age effects with:

          -  ~30 being 3 - &lt;6 years

          -  â‰¥35% (n â‰¥123) being 6 - &lt;12 years

          -  â‰¥35% (n â‰¥123) being 12 - &lt;18 years PK sub group at selected sites includes 24
             participates, details in protocol.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parent/guardian has provided informed consent

          2. Participant has provided assent if developmentally appropriate and as required by the
             institutional review board (IRB)

          3. 3 - &lt;18 years of age inclusive at time of M0 visit

          4. Participant, when developmentally appropriate, and parent/guardian are:

               1. Willing to authorize exchange of information between the SS and the participant's
                  PPPMP and/or other significant medical provider

               2. Affirm participant's use at M0 visit of either risperidone or aripiprazole
                  mono-antipsychotic therapy as prescribed by participant's PPPMP

          5. Based on their age at the time of M0 visit, participant is receiving aripiprazole or
             risperidone at the dose and for the diagnoses as listed below:

               1. Participants ages 3 - &lt; 6 years can have any diagnosis and any dose

               2. Participants ages â‰¥ 6 - &lt;18 years at the doses and for the diagnoses listed below

                  Labeled Indications (Closely Related Disorders)

                  Aripiprazole 2-30 mg/day

                    -  Irritability associated with autistic disorder:

                  (Irritability in autism spectrum disorder) - Treatment of Tourette's disorder:
                  (Tourette's disorder, persistent (chronic) motor or vocal tic disorder) - Bipolar
                  mania/acute treatment of manic and mixed episodes associated with Bipolar l
                  disorder: (Bipolar spectrum disorders including disruptive mood dysregulation
                  disorder)

                  - Schizophrenia: (Schizophrenia spectrum disorders including schizoaffective
                  disorder, psychosis not otherwise specified, and delusional disorder)

                  Risperidone 0.25-6 mg/day

                  - Irritability associated with autistic disorder: (Irritability in autism
                  spectrum disorder)

                  - Bipolar Mania: (Bipolar spectrum disorders including disruptive mood
                  dysregulation disorder)

                  - Schizophrenia: (Schizophrenia spectrum disorders including schizoaffective
                  disorder, psychosis not otherwise specified, and delusional disorder)

                    -  MYCITEÂ® (aripiprazole) and all forms of injectables are not permitted in
                       this study

          6. Guardian anticipates risperidone or aripiprazole treatment will continue for â‰¥6 months

        Exclusion Criteria:

          1. History of prior or current diagnosis of an eating disorder or meets diagnostic
             criteria for an eating disorder as described in the Diagnostic and Statistical Manual
             of Mental Disorders, Fifth Edition (DSM-5) and determined by psychiatric exam

          2. Pre-existing or suspected major medical, metabolic, or genetic condition that is
             expected to be associated with weight, cardiovascular, neuromotor, or endocrine
             problems

          3. Known or self-reported pregnancy

          4. Taking antipsychotic medication other than either risperidone or aripiprazole at the
             time of M0 visit

          5. Contraindications to participation in the study in the opinion of the SMC

          6. Unwilling or unable to provide back-up family contact information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linmarie Sikich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institution (DCRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Watt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Alderman</last_name>
    <phone>919-668-8349</phone>
    <email>cheryl.alderman@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Taylor</last_name>
    <phone>919.668.1186</phone>
    <email>sarah.r.taylor@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Baldwin</last_name>
      <phone>334-836-2000</phone>
      <email>bbaldwin@harmonex.us</email>
    </contact>
    <contact_backup>
      <last_name>Amellia Brackin</last_name>
      <phone>334-836-2000</phone>
      <email>abrackin@harmonex.us</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Southwest Autism Research &amp; Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kiefer</last_name>
      <phone>602-218-8183</phone>
      <email>SKiefer@autismcenter.org</email>
    </contact>
    <contact_backup>
      <last_name>Padmaja Lakamsani</last_name>
      <phone>602-218-8207</phone>
      <email>plakamsani@autismcenter.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Research Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole McBride</last_name>
      <phone>501-364-4188</phone>
      <email>nmcbride@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nihit Kumar</last_name>
      <phone>501-364-1992</phone>
      <email>nkumar@uams.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OM Research</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93594</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayisha Stafford</last_name>
      <phone>661-388-2239</phone>
      <email>mstafford@omclinicaltrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Robert Imani</last_name>
      <phone>1-661-388-2239</phone>
      <email>rimani@omclinicaltrials.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCLA Semel Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cowen</last_name>
      <phone>310-825-6170</phone>
      <email>jcowen@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Child Study Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Zakur</last_name>
      <phone>203-785-6906</phone>
      <email>david.zakur@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Levine</last_name>
      <phone>203-785-6906</phone>
      <email>jessica.levine@yale.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South Florida Behavioral Health Network</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thresia Gambon</last_name>
    </contact>
    <contact_backup>
      <last_name>John Newcomer</last_name>
      <phone>305-860-0653</phone>
      <email>jnewcomer@sfbhn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South Florida Behavioral Health Network</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maristrealla Moriffi-Pla</last_name>
      <phone>786-441-5368</phone>
      <email>mmorffipla@citrushealth.com</email>
    </contact>
    <contact_backup>
      <last_name>John Newcomer</last_name>
      <phone>305-860-0653</phone>
      <email>jnewcomer@sfbhn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Solution</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Mendoza</last_name>
      <phone>786-372-1836</phone>
      <email>cmendoza@ctsolutionscorp.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Carballosa</last_name>
      <email>mcarballosa@eliasresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South Florida Behavioral Health Network</name>
      <address>
        <city>Key Largo</city>
        <state>Florida</state>
        <zip>33037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denise Costa</last_name>
      <phone>305-434-7660</phone>
      <email>denise.costa@westcare.com</email>
    </contact>
    <contact_backup>
      <last_name>John Newcomer</last_name>
      <phone>305-860-0653</phone>
      <email>jnewcomer@sfbhn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South Florida Behavioral Health Network</name>
      <address>
        <city>Key West</city>
        <state>Florida</state>
        <zip>33040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annie Rojas</last_name>
      <phone>305-434-7660</phone>
      <email>mirta.rojas@westcare.com</email>
    </contact>
    <contact_backup>
      <last_name>John Newcomer</last_name>
      <phone>305-860-0653</phone>
      <email>jnewcomer@sfbhn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South Florida Behavioral Health Network</name>
      <address>
        <city>Marathon</city>
        <state>Florida</state>
        <zip>33050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Marcinak</last_name>
      <email>lisa.marcinak@westcare.com</email>
    </contact>
    <contact_backup>
      <last_name>John Newcomer</last_name>
      <phone>305-860-0653</phone>
      <email>jnewcomer@sfbhn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Cenci</last_name>
      <phone>305-722-8444</phone>
      <email>lcenci@segaltrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Jenny Rojas</last_name>
      <phone>305-722-8444</phone>
      <email>jrojas@segaltrials.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cutts</last_name>
      <phone>706-320-8752</phone>
      <email>jcutts@iacthealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Brown-Gullatt</last_name>
      <phone>706-321-0495</phone>
      <email>kgullatt@iacthealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Grayson</city>
        <state>Georgia</state>
        <zip>30017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Scallon</last_name>
      <phone>678-573-1721</phone>
      <email>nscallon@iacthealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Patel</last_name>
      <phone>678-938-0987</phone>
      <email>bpatel@iacthealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Attalla Consultants, LLC dba Institute for Behavioral Medicine</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30082-2629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Strommen</last_name>
      <phone>770-319-8025</phone>
      <email>manager@drashrafattalla.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashraf Attalla</last_name>
      <phone>770-319-8025</phone>
      <email>pi@drashrafattalla.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AMR-Baber Research, Inc.</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freeda Baber</last_name>
      <phone>630-272-4844</phone>
      <email>freeda@baberresearchgroup.com</email>
    </contact>
    <contact_backup>
      <last_name>Tina Marzullo</last_name>
      <phone>630-844-2095</phone>
      <email>tina@baberresearchgroup.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beacon Medical Group</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Kuespert</last_name>
      <phone>574-647-6584</phone>
      <email>skuespert@beaconhealthsystem.org</email>
    </contact>
    <contact_backup>
      <last_name>Toni Riehm</last_name>
      <phone>574-647-7883</phone>
      <email>triehm@beaconhealthsystem.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Brown</last_name>
      <email>brownjes@kennedykrieger.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Geller</last_name>
      <email>dan.geller@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Smilansky</last_name>
      <phone>1-617-726-5527</phone>
      <email>hsmilansky@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital, Lurie Center for Autism</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mullett</last_name>
      <phone>781-860-1710</phone>
      <email>jmullett@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karyn Wagner</last_name>
      <phone>781-860-1711</phone>
      <email>LurieCenterResearch@partners.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Foley</last_name>
      <phone>774-455-4100</phone>
      <email>ChildResearch@umassmed.edu</email>
    </contact>
    <contact_backup>
      <phone>774-455-4103</phone>
      <email>Ann.Foley@umassmed.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Medicine Group</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Ulrich</last_name>
      <phone>248-766-7466</phone>
      <email>laurenu@neurobmg.com</email>
    </contact>
    <contact_backup>
      <last_name>Richard Jackson</last_name>
      <phone>248-290-5400</phone>
      <email>rjacksonmd@neurobmg.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pine Rest Christian Mental Health Services</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49548</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heide Rollings</last_name>
      <phone>616-281-6363</phone>
      <email>heide.rollings@pinerest.org</email>
    </contact>
    <contact_backup>
      <last_name>LeAnn Smart</last_name>
      <phone>616-222-4592</phone>
      <email>leann.smart@pinerest.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Holmes</last_name>
      <phone>601-815-4179</phone>
      <email>jyholmes@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Annett</last_name>
      <phone>601-815-4517</phone>
      <email>rannett@umc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Portnoy</last_name>
      <phone>314-362-2423</phone>
      <email>steveportnoy@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ginger Nicol</last_name>
      <phone>314-362-5939</phone>
      <email>nicolg@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigette Vaughan</last_name>
      <phone>402-559-4949</phone>
      <email>bvaughan@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Soonjo Hwang</last_name>
      <phone>402-552-6002</phone>
      <email>soonjo.hwang@unmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Shanahan</last_name>
      <phone>718-839-7520</phone>
      <email>eshanaha@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Bonnie Taylor</last_name>
      <phone>(718) 839-7530</phone>
      <email>botaylor@montefiore.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shazad Ali</last_name>
      <phone>984-974-9646</phone>
      <email>shahzad_ali@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Pugliese</last_name>
      <phone>919-962-9729</phone>
      <email>elizabeth_pugliese@med.unc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke Child and Family Study Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Chandrasekhar</last_name>
      <phone>919-385-3232</phone>
      <email>tara.chandrasekhar@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marina Spanos</last_name>
      <phone>919-681-3834</phone>
      <email>marina.spanos@duke.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Behavioral Health Hospital Oupatient Clinic</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Millikan</last_name>
      <phone>336-832-9615</phone>
      <email>debra.millikan@conehealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Shawn Taylor</last_name>
      <phone>336-832-9800</phone>
      <email>shawn.taylor@conehealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carolina Partners in Mental HealthCare, PLLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Guile</last_name>
      <phone>919-792-3940</phone>
      <email>lee.guile@carolinapartners.com</email>
    </contact>
    <contact_backup>
      <last_name>Meghan Fitzgerald</last_name>
      <phone>1-919-792-3940</phone>
      <email>meghan.fitzgerald@carolinapartners.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2492</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sireesha Pothukuchi</last_name>
      <phone>513-558-0002</phone>
      <email>pothuksa@ucmail.uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gayathri Pulapaka</last_name>
      <phone>513-558-8621</phone>
      <email>gayathri.kavikondala@uc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Avera McKennan University Psychiatry Associates</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Flynn</last_name>
      <phone>605-322-5707</phone>
      <email>sarah.flynn@usd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Moncur</last_name>
      <phone>605-322-5727</phone>
      <email>amy.moncur@avera.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracee Ridley</last_name>
      <phone>901-287-5338</phone>
      <email>tridley@uthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Arnold</last_name>
      <phone>901-843-1045</phone>
      <email>varnold@uthsc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Flores</last_name>
      <phone>512-586-4250</phone>
      <email>ruth@bbraustin.com</email>
    </contact>
    <contact_backup>
      <last_name>Alexsandria DeLeon</last_name>
      <phone>1-512-382-6661</phone>
      <email>alexsandria@bbraustin.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurie Bailey</last_name>
      <phone>682-885-2488</phone>
      <email>laurie.bailey@cookchildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Alice Hoeft</last_name>
      <email>alice.hoeft@cookchildrens.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadi Calarge</last_name>
      <phone>832-824-4764</phone>
      <email>chadi.calarge@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Griselda Barba Villalobos</last_name>
      <phone>1-832-824-4764</phone>
      <email>griselda.barbavillalobos@bcm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wilson</last_name>
      <phone>802-457-4904</phone>
      <phone_ext>106</phone_ext>
      <email>jwilson@woodstockresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Sue Shaw</last_name>
      <email>sshaw@woodstockresearch.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Muniz</last_name>
      <phone>434-243-3678</phone>
      <email>kmm8ab@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gina Snow</last_name>
      <phone>434-924-7046</phone>
      <email>gms4x@hscmail.mcc.virginia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Group, PLLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terrie Conklin</last_name>
      <phone>757-668-9356</phone>
      <email>terrie.conklin@chkd.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Chagnon</last_name>
      <phone>757-668-9920</phone>
      <email>sarah.chagnon@chkd.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Daniel Benjamin</investigator_full_name>
    <investigator_title>Kiser-Arena Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data collected is uploaded into the National Institute of Health data repository (DASH) at the end of the study (de-identified).</ipd_description>
    <ipd_time_frame>Data will be uploaded to the repository within 2 years of study completion. It will be maintained in the repository indefinitely.</ipd_time_frame>
    <ipd_access_criteria>In order to have access, researchers have to complete a Data access request. NICHD will review the request and either approve or deny it. IRB approval must be obtained by the researcher to access the data.
https://dash.nichd.nih.gov/Resource/DataRequestChecklist</ipd_access_criteria>
    <ipd_url>https://dash.nichd.nih.gov/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03522168/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

